GENFIT ORDINARY SHARES FRANCE (OTCMKTS:GNFTF) had an increase of 30.94% in short interest. GNFTF’s SI was 377,100 shares in June as released by FINRA. Its up 30.94% from 288,000 shares previously. With 200 avg volume, 1886 days are for GENFIT ORDINARY SHARES FRANCE (OTCMKTS:GNFTF)’s short sellers to cover GNFTF’s short positions. The SI to GENFIT ORDINARY SHARES FRANCE’s float is 1.28%. It closed at $27.55 lastly. It is down 0.00% since June 20, 2017 and is . It has underperformed by 12.57% the S&P500.
Tci Wealth Advisors Inc increased Brown Forman Corp (BF.B) stake by 31.74% reported in 2018Q1 SEC filing. Tci Wealth Advisors Inc acquired 6,585 shares as Brown Forman Corp (BF.B)’s stock 0.00%. The Tci Wealth Advisors Inc holds 27,334 shares with $1.49M value, up from 20,749 last quarter. Brown Forman Corp now has $24.29 billion valuation. The stock decreased 2.51% or $1.32 during the last trading session, reaching $51.19. About 603,544 shares traded. Brown-Forman Corporation (NYSE:BF.B) has risen 40.18% since June 20, 2017 and is uptrending. It has outperformed by 27.61% the S&P500. Some Historical BF.B News: ; 07/03/2018 – BROWN-FORMAN CORP BFb.N SEES FY 2018 ADJUSTED SHR $1.43 TO $1.48; 21/03/2018 – Brown-Forman Names Tracy Skeans to Board; 16/05/2018 – Brown-Forman Refines Organization to Support Continued Strong Global Growth; 07/03/2018 – RPT-BROWN-FORMAN CORP BFB.N FY2018 SHR VIEW $1.59, REV VIEW $3.24 BLN — THOMSON REUTERS l/B/E/S; 22/03/2018 – GUIDANCE: Brown-Forman $300m 7Y, $300m 20Y; 07/03/2018 – RPT-BROWN-FORMAN CORP – REVISES FISCAL YEAR 2018 OUTLOOK; 29/05/2018 – Brown-Forman: Paul Varga to Retire as CEO; 16/05/2018 – Brown-Forman: New Organization to Be Led by Mike Keyes; 07/03/2018 – RPT-BROWN-FORMAN – SEES 2018 DILUTED EPS OF $1.43 TO $1.48; 22/03/2018 – Brown-Forman Announces $600 Million Debt Offering
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases with a focus on the liver and gastroenterology worldwide. The company has market cap of $854.85 million. It offers diagnostic solutions in various therapeutic areas, such as metabolic diseases, liver diseases, non-alcoholic steato-hepatitis , cholestatic liver diseases, inflammation and autoimmune diseases, and inflammatory bowel diseases. It currently has negative earnings. The companyÂ’s lead pipeline product comprises GFT505, which is in Phase II clinical trials for the treatment of NASH.
More recent Brown-Forman Corporation (NYSE:BF.B) news were published by: Seekingalpha.com which released: “Brown-Forman Corporation (BF.B) CEO Paul Varga on Q4 2018 Results – Earnings Call Transcript” on June 06, 2018. Also Globenewswire.com published the news titled: “Consolidated Research: 2018 Summary Expectations for Microchip Technology, New Jersey Resources, Brown …” on June 18, 2018. Seekingalpha.com‘s news article titled: “Ross: EU will determine tariff escalation” with publication date: May 31, 2018 was also an interesting one.
Among 12 analysts covering Brown-Forman (NYSE:BF.B), 1 have Buy rating, 2 Sell and 9 Hold. Therefore 8% are positive. Brown-Forman had 43 analyst reports since July 21, 2015 according to SRatingsIntel. Cowen & Co maintained Brown-Forman Corporation (NYSE:BF.B) on Thursday, August 31 with “Hold” rating. On Wednesday, March 8 the stock rating was maintained by Stifel Nicolaus with “Hold”. The firm has “Hold” rating by RBC Capital Markets given on Thursday, March 8. Goldman Sachs upgraded it to “Hold” rating and $56.0 target in Thursday, September 28 report. The firm has “Hold” rating given on Wednesday, December 6 by Stifel Nicolaus. RBC Capital Markets maintained Brown-Forman Corporation (NYSE:BF.B) rating on Friday, June 23. RBC Capital Markets has “Hold” rating and $5100 target. Sterne Agee CRT initiated the shares of BF.B in report on Tuesday, July 21 with “Buy” rating. Cowen & Co maintained Brown-Forman Corporation (NYSE:BF.B) on Thursday, July 13 with “Hold” rating. Credit Suisse downgraded Brown-Forman Corporation (NYSE:BF.B) on Thursday, June 8 to “Hold” rating. As per Wednesday, March 7, the company rating was upgraded by Pivotal Research.